NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ATS ...

The pulmonary sarcoidosis treatment landscape is poised for substantial transformation, primarily driven by the development of targeted therapeutics, improved diagnostic approaches, and rising disease ...

The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients receiving efzofitimod vs. placebo were steroid-free with a stable/improved King ...

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters ...

BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and ...

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON ...

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development of namilumab for the treatment of sarcoidosis will be discontinued Primary Endpoint Details: ...

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development of namilumab for the treatment of sarcoidosis will be discontinued Primary Endpoint Details: ...

(MENAFN- IMARC Group) According to the IMARC Group, the pulmonary sarcoidosis market exhibited a market size reached a value of USD 19.5 Billion in 2024. Looking forward, IMARC Group expects the top 7 ...